{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T10:20:33Z","timestamp":1791109233111,"version":"4.1.0"},"reference-count":17,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2007,1,16]],"date-time":"2007-01-16T00:00:00Z","timestamp":1168905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2007,3]]},"abstract":"<jats:sec><jats:title>Summary<\/jats:title><\/jats:sec><jats:sec><jats:title>Background<\/jats:title><jats:p>Adalimumab is effective in inducing remission in patients with active Crohn\u2019s disease who had secondary failure to infliximab therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate the efficacy and safety of adalimumab maintenance therapy in Crohn\u2019s disease patients who previously responded to infliximab and then lost response or became intolerant.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Twenty\u2010four patients with Crohn\u2019s disease were enrolled in a 52\u2010week open\u2010label trial. The patients received a loading dose of adalimumab 80\u2010mg at week 0, and then 40\u2003mg every other week starting at week 2. The primary efficacy measure was clinical remission defined as Crohn\u2019s Disease Activity Index score\u2003&lt;\u2003150\u2003at week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five patients lost response to adalimumab. None of the patients experienced intolerance to adalimumab. Clinical remission rates were higher at weeks 4 (16\/24, 67%) and 52 (14\/24, 58%) compared with baseline (8\/24, 35%) (<jats:italic>P\u2003<\/jats:italic>=\u20030.043 at week 52). This was accompanied by a decrease in mean C\u2010reactive protein concentration from 31.8\u2003mg\/mL at baseline to 9.7\u2003mg\/mL at week 52, and 3\/4 (75%) patients achieved steroid\u2010free remission. No serious toxicities occurred in the study.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Adalimumab is well tolerated and appears to be effective in maintaining clinical remission in patients with Crohn\u2019s disease and lost response or intolerance to infliximab.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2036.2007.03254.x","type":"journal-article","created":{"date-parts":[[2010,7,23]],"date-time":"2010-07-23T11:02:12Z","timestamp":1279882932000},"page":"675-680","source":"Crossref","is-referenced-by-count":55,"title":["Adalimumab maintenance therapy for Crohn\u2019s disease with intolerance or lost response to infliximab: an open\u2010label study"],"prefix":"10.1111","volume":"25","author":[{"given":"L.","family":"PEYRIN\u2010BIROULET","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"LACLOTTE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.\u2010A.","family":"BIGARD","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,1,22]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.40.4.443"},{"key":"e_1_2_6_3_2","first-page":"1029\u201335","article-title":"A short\u2010term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn\u2019s disease. Crohn\u2019s Disease cA2 Study Group","volume":"15","author":"Targan SR","year":"1997","journal-title":"N Engl J Med"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08512-4"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2003.50145"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00238-1"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)01034-5"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.11.030"},{"key":"e_1_2_6_10_2","article-title":"Adalimumab for maintenance treatment of Crohn\u2019s disease: results of the CLASSIC\u2010II trial","author":"Sandborn WJ","journal-title":"Gut"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2006.11.041"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.06.064"},{"issue":"2","key":"e_1_2_6_13_2","first-page":"A107","article-title":"Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn\u2019s disease: results from a 26\u2010week, placebo\u2010controlled phase III study (PRECISE 1)","volume":"130","author":"Sandborn WJ","year":"2006","journal-title":"Gastroenterology"},{"key":"e_1_2_6_14_2","first-page":"A82","article-title":"Certolizumab pegol, a humanised anti\u2010TNF pegylated Fab\u2032 fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn\u2019s disease: a phase III study (PRECISE)","volume":"54","author":"Schreiber S","year":"2005","journal-title":"Gut"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2004.40462.x"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00054725-200407000-00002"},{"key":"e_1_2_6_17_2","first-page":"A21","article-title":"Adalimumab rapidly induces clinical response and remission in patients with moderate to severe Crohn\u2019s disease who had secondary failure to infliximab therapy: results of the GAIN study","volume":"55","author":"Rutgeerts P","year":"2006","journal-title":"Gut"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2005.40647.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2007.03254.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2007.03254.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,15]],"date-time":"2023-10-15T18:15:18Z","timestamp":1697393718000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2007.03254.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,1,22]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007,3]]}},"alternative-id":["10.1111\/j.1365-2036.2007.03254.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2007.03254.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,1,22]]}}}